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A B S T R A C T
Introduction and aim: Microangiopathy is a hallmark of systemic sclerosis (SSc). It is a progressive process from
an early inﬂammatory and proangiogenic environment to insuﬃcient microvascular repair with loss of micro-
vessels. The exact underlying mechanisms remain ill-deﬁned. Aim of the study was to investigate whether im-
balanced angiopoietins/VEGF serum proﬁle should be related in SSc to the altered microvascular reactivity
characterized by aberrant angiogenesis and avascularity.
Materials and methods: Serum levels of Angiopoietin-1 (Ang1), Angiopoietin-2 (Ang2) and VEGF were measured
by ELISA in 47 SSc patients and 27 healthy controls. Microvascular alterations were assessed by nailfold vi-
deocapillaroscopy (NVC).
Results: Serum concentrations of Ang1 were signiﬁcantly lower [mean (S.D.): 21516.04 (11,441.035) pg/ml],
and Ang2 signiﬁcantly increased [25,89.55 (934.225) pg/ml] in SSc as compared with the control group [Ang1:
28,457.08 (10,431.905) pg/ml; Ang2: 1556.23 (481.255) pg/ml, p < 0.01, respectively], whereas VEGF did not
diﬀer signiﬁcantly. The ratios of Ang1/Ang2 and Ang1/VEGF were signiﬁcantly lower in SSc patients
(8.346 ± 4.523 and 95.17 ± 75.0, respectively) than in healthy subjects (17.612 ± 6.731 p < 0.000001 and
183.11 ± 137.73; p= 0.004]. Formation of giant capillaries with vascular leakage and collapse was associated
with signiﬁcant increase in VEGF and concomitant Ang1 deﬁciency. Capillary loss was related to signiﬁcant
increase in VEGF with respect to those with preserved capillary number (395.12 ± 256.27 pg/mL vs.
254.80 ± 213.61 pg/mL) whereas elevated Ang2 levels induced more advanced capillary damage as indicated
by the presence of the “Late” NVC pattern.
Conclusions: We found that serum levels of Ang1, Ang2 and VEGF are diﬀerentially expressed in SSc and altered
Ang1/Ang2 proﬁle might underlay the aberrant angiogenesis in SSc despite increase in VEGF. For the ﬁrst time
we identiﬁed that signiﬁcant deﬁciency of Ang1 might be involved in early capillary enlargement, followed by
collapse and lack of stable newly-formed vessels in VEGF-enriched environment, whereas Ang2 levels seem to
increase later in disease progression and advanced microvascular damage (“Late” NVC pattern).
1. Introduction
Vascular alterations in SSc predominantly aﬀect the micro-
vasculature and are primarily due to endothelial cells (ECs) injury
(activation/apoptosis) resulting from perivascular immune and
inﬂammatory reaction. It leads to loss of endothelium integrity with
ECs detachment and in consequence to deformations of microvessels
with signiﬁcant enlargement of the capillaries followed by capillary
collapse and rarefaction (Altorok et al., 2014; Cutolo and Sulli, 2015;
Fleming and Schwartz, 2008; Freemont et al., 1992; Kahaleh, 2008;
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Manetti et al., 2010; Matucci-Cerinic et al., 2017). These speciﬁc se-
quential abnormalities in microcirculation are reﬂected by nailfold vi-
deocapillaroscopy (NVC) morphological changes in form of enlarged
loops/giants, capillary crush with microhaemorrhages and capillary
loss (Cutolo et al., 2004, 2013, 2018; Ghizzoni et al., 2015; Smith et al.,
2016a, 2016b). Decreased blood ﬂow and tissue hypoxia normally sti-
mulates angiogenesis with the formation of new capillaries from pre-
existing vessels; however in SSc subsequent proangiogenic eﬀorts lead
to chaotic and insuﬃcient vascular regeneration that ﬁnally evolves
towards progressive microvascular loss further exacerbated by extra-
cellular matrix (ECM) accumulation and progressive ﬁbrosis (Distler
et al., 2006; Kuwana et al., 2004; Manetti et al., 2010, 2016; Matucci-
Cerinic et al., 2017; Mulligan-Kehoe and Simons, 2008). This is evident
by the presence at NVC analysis of chaotic unstable neoangiogenetic
tree-like capillaries and avascular areas and may be thought a paradox
since increased serum and skin levels of proangiogenic factors have
been found in SSc patients (Avouac et al., 2008; Chora et al., 2015;
Cutolo et al., 2004; Distler et al., 2003, 2004; Dunne et al., 2013;
Fleming and Schwartz, 2008; Freemont et al., 1992; Kahaleh, 2008;
Mackiewicz et al., 2002; Manetti et al., 2010; Solanilla et al., 2009;
Sysa-Jędrzejowska et al., 2004).
Among them, unexpectedly, chronic overexpression of the strongest
angiogenic inducer - vascular endothelial growth factor (VEGF) has
been reported and associated with the severity of capillary architectural
derangement and loss (Chora et al., 2015; Distler et al., 2004;
Mackiewicz et al., 2002; Manetti et al., 2010; Sysa-Jędrzejowska et al.,
2004).
More recently, two endothelial speciﬁc growth factors,
Angiopoietin-1 (Ang1) and Angiopoietin-2 (Ang2) have been clariﬁed
to interact with VEGF to determine the fate of blood vessels during
angiogenesis. The interaction of speciﬁc tyrosine kinase receptor (Tie2)
with Ang1/Ang2 seems to exert dual eﬀects on vascular endothelium
and angiogenesis in a context-dependent manner. Ang/Tie2 system is
essential for controlling sprouting angiogenesis, vascular remodelling
and the transition between the quiescent and the activated status of ECs
during adult vessel homeostasis (Asahara et al., 1998; Eklund and
Saharinen, 2013; Fagiani and Christofori, 2013; Holash et al., 1999a,
1999b; Loughna and Sato, 2001; Loukovaara et al., 2013; Peters et al.,
2004; Thurston, 2003).
Since new blood vessel formation results from complementary ac-
tion of VEGF and angiopoietins, we hypothesized that derangement of
capillary morphology, aberrant angiogenesis and ﬁnal loss of vascular
regeneration as observed in SSc might be also related to an impaired
cooperation of these factors. To test this hypothesis, we assessed whe-
ther serum levels of Ang1, Ang2, VEGF and mainly their ratios might be
abnormal in sera of SSc patients looking for any possible association
with speciﬁc morphological alterations in microvessels morphology as
objectiﬁed by NVC in the same patients.
2. Material and methods
2.1. Patients
Forty-seven consecutive SSc patients with a mean (range) age 56.43
(34–79) years and mean (range) disease duration of 9.99 (2–34) years,
referred to our institution over a 2-year, were included to the study. All
patients were women and fulﬁlled the ACR/EULAR classiﬁcation cri-
teria for SSc (Subcommittee for scleroderma criteria of the American
Rheumatism Association, 1980; van den Hoogen et al., 2013). The
control group consisted of 27 healthy age-matched women. Patients
with overlap syndromes, diabetes mellitus, hyperlipidaemia, throm-
bosis, pregnancy, neoplastic diseases and those with habitual cigarette
smoking and alcohol drinking were excluded from the study. All pa-
tients were on stable treatment regimen for at least 6 months, including
low-dose prednisone (≤10mg/day), vasodilators (calcium channel
blockers or angiotensin-converting enzyme inhibitors), pentoxiﬁlline
(800mg/day) and 15 of them had received pulsed intravenous cyclo-
phosphamide (CYC) every month; however, blood samples were drawn
at least 2 months after the last course of the pulsed CYC therapy. No
patient was treated with prostacyclin at the time of the study and none
of the patients was on endothelin receptor antagonists.
The experimental protocol in this study has been approved by the
research committee at the Bioethic Committee at the Medical
University of Lublin. The study complies with Declaration of Helsinki.
All participants gave their informed consent.
Patients had a detailed laboratory and clinical assessment at the
same hospitalization as the blood samples were drawn. The criteria
used for clinical assessment as well as detailed clinical characteristics of
SSc patients are as provided elsewhere (Michalska-Jakubus et al., 2011,
2017). Baseline demographic and clinical data of SSc patients and
healthy controls are shown in Table 1.
2.2. Nailfold videocapillaroscopy (NVC) and qualitative capillaroscopic
assessment
All patients underwent a nailfold videocapillaroscopy (NVC) per-
formed and assessed in a blind manner by using a VideoCap 3.0
equipped with a x200 magniﬁcation optical probe and connected to
image-analysis software (DS Medica, Milano, Italy) by two independent
experienced investigators blinded for the clinical and serum status of
SSc patients (MM-J and OK-B). Each patient was allowed to acclimatize
to room temperature (22 to 23 °C) for at least 20min before examina-
tion. Patients were asked not to smoke, take caﬀeinated drinks and
vasodilators for at least 24 h before NVC. The nailfolds of 8 ﬁngers
(except the thumbs and ﬁngers aﬀected by recent local trauma) were
examined and four consecutive ﬁelds extending over 1mm, in the
middle of the nailfold were studied per ﬁnger looking for the presence
of pericapillary oedema, giant capillaries and microhaemorrhages, ra-
miﬁed capillaries (neoangiogenetic loops), loss of capillaries, avascular
areas and disorganization of the capillary array as described elsewhere
(Cutolo et al., 2004, 2018; Smith et al., 2016a, 2016b). In addition, the
most speciﬁc features of SSc microangiopathy, i.e. capillary number
(capillary reduction), number of giant loops and ramiﬁed capillaries
were scored semiquantitatively. In brief, 16 ﬁelds each of 1mm were
analysed in the middle of the nailfold per 8 ﬁngers. The intensity of
each parameter was scored 0–3, where 0=no capillary alterations
or> 9 capillaries per linear mm, 1= <33% of capillary alterations or
capillary reduction (7–9 capillaries/linear mm), 2= 33–66% of capil-
lary alterations or capillary reduction (4–6 capillaries/linear mm),
3= >66% of capillary alterations or capillary reduction (1–3 capil-
laries/linear mm). Based on the NVC ﬁndings patients were classiﬁed
Table 1
Demographic and clinical characteristics of patients with systemic sclerosis
(SSc) and healthy controls.
Parameters SSc patients (n= 47) Healthy controls (n= 27)
Age [years]: mean ± SD
(range)
56.43 ± 11.01
(34–79)
52.37 ± 8.87(38–80)*
Female/male ratio 47/0 27/0*
Disease subset
• Limited (lcSSc), n (%)• Diﬀuse (dcSSc), n (%)
40 (85)
7 (15)
Disease duration [years]:
mean ± SD (range)
9.99 ± 6.96 (2–34)
Antinuclear antibodies:
• ANA positive, n (%)• Anti-Scl-70 positive, n
(%)
• ACA positive, n (%)
45 (96)
26 (55)
17 (36)
Capillaroscopic pattern:
• Early• Active• Late
14 (30)
14 (30)
19 (40)
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into 3 groups showing an “Early”, “Active” or “Late” pattern, according
to Cutolo et al. (2004). The “Early” NVC pattern was deﬁned as the
combination of few (scored 1 or 2) enlarged/giant capillaries and mi-
crohaemorrhages, a relatively well-preserved (scored 0 or 1) capillary
distribution, and no evident loss of capillaries (≥9/linear mm; scored
0); the “Active” NVC pattern as frequent (scored 3) giant capillaries and
microhaemorrhages, moderate loss (scored 1 or 2) of capillaries, mild
disorganization (scored 2) of the capillary architecture, and absent or
mild (scored 0 to 1) ramiﬁed capillaries; the “Late” NVC pattern as few
or absent giant capillaries and microhaemorrhages, severe loss of ca-
pillaries (scored 3) with large avascular areas, severe (scored 3) dis-
organization of the normal capillary array, and frequent (scored 2 or 3)
ramiﬁed/bushy capillaries (Cutolo et al., 2004).
2.3. Serum specimen preparation and detection of angiogenic factors
Blood samples were taken at rest from the forearm, in the morning,
then clotted for 30min and centrifuged for 10min at 1000g. Serum
aliquots were frozen at −80 degrees of C immediately after collection.
Serum concentrations of Ang1, Ang2 and VEGF were measured by
commercially available sandwich ELISA (Quantikine R&D Systems,
Minneapolis, MN, USA) according to the manufacturer's instructions.
The anti-pan-VEGF was used (cat. no. DVE00) that detect both detect
both VEGF165b and VEGF165 isoforms. The values were calculated
using a standard curve generated with speciﬁc standards provided by
the manufacturer. The minimum detectable concentration of Ang1
was<3.45 pg/mL, Ang2 < 8.29 pg/mL and VEGF<9 pg/mL.
2.4. Statistical analysis
First, the numerical variables distribution was assessed by the
Shapiro-Wilk test. The values of Ang1, Ang2 and VEGF serum levels
were not normally distributed; therefore, non-parametric tests were
employed for further analysis. The results were expressed as mean,
standard deviation (SD) and range. Comparisons of numerical values
between patients with SSc and healthy controls and within the patient
group were performed by the Mann-Whitney U test and Wilcoxon
signed-rank test, as appropriate. Data were correlated by Spearman's
rank correlation test. p < 0.05 was considered as statistically sig-
niﬁcant.
3. Results
3.1. Qualitative NVC assessment
Morphological changes of microvasculature corresponding with the
diﬀerent scleroderma patterns were observed in NVC among all studied
SSc patients, whereas capillaroscopic picture in the control group
showed hairpin capillaries in a parallel arrangement. According to
criteria proposed by Cutolo et al. (2004), an “Early” capillaroscopic
pattern was found in 14 (29,79%), “Active” in 14 (29,79%), and “Late”
in 19 (40,42%) of 47 SSc patients.
3.2. Serum levels of Ang1, Ang2 and VEGF in SSc patients and the control
group
The mean concentrations of Ang1, An2 and VEGF did not diﬀer
signiﬁcantly between 15 SSc patients who were on CFX therapy when
enrolled into the study as compared with the remaining 32 SSc patients
(data not shown). Therefore, those 15 patients on CFX were included
into further analyses.
We detected a signiﬁcant decrease in serum level of Ang1 [mean
(S.D.): 21516.04 (11,441.035) pg/mL] and signiﬁcant increase of Ang2
[2589.55 (934.225) pg/mL] in SSc patients with respect to normal
controls [28,457.08 (10,431.905) pg/mL, p < 0.01 for Ang1 and
1556.23 (481.255) pg/mL, p < 0.001 for Ang2]. Serum levels of VEGF
did not diﬀer signiﬁcantly from those of controls
(329.44 ± 245.16 pg/mL vs. 233.99 ± 138.30; p > 0.05).
Accordingly, the Ang1/Ang2 ratio was signiﬁcantly lower in SSc pa-
tients (8.346 ± 4.523) than in healthy subjects (17.612 ± 6.731),
p < 0.000001] (Table 2). Moreover, SSc patients exhibited sig-
niﬁcantly decreased Ang1/VEGF ratio (95.17 ± 75.0) than did control
group (183.11 ± 137.73; t=−3.07, p=0.004). Values of Ang2/
VEGF ratio did not diﬀer signiﬁcantly between SSc patients and healthy
individuals (Table 3). There was no signiﬁcant correlation between
serum levels of Ang1, Ang2 and VEGF among patient group (r=0.210,
p > 0.05) (Table 4).
3.3. Serum levels of Ang1, Ang2 and VEGF according to NVC ﬁndings
Regarding to NVC patterns, serum concentrations of Ang2 were
signiﬁcantly increased in patients with the “Late” NVC pattern
(2899.19 ± 788.375 pg/mL, p < 0.05) when compared with those
SSc patients who had capillaroscopic changes typical of “Active” NVC
pattern (2323.53 ± 940.695 pg/mL, p < 0.05). Serum levels of Ang2
in SSc subjects with “Late” capillaroscopy pattern were also higher, but
not signiﬁcantly diﬀerent, than in patients with “Early” changes
(2899.19 ± 788.375 vs. 2435.35 ± 1064.435 pg/mL; p > 0.05). In
contrast, no signiﬁcant diﬀerences in the levels of either Ang1 or VEGF
were found between the three capillaroscopy groups of SSc patients;
however there was tendency to higher VEGF in patients with “Late”
NVC pattern. The distribution of serum levels of Ang2 and VEGF ac-
cording to NVC scleroderma pattern is presented in Fig. 1.
To better understand the potential role of angiopoietins/VEGF
aberrant balance in SSc-related microangiopathy, we further analysed
relationships between their levels and particular vascular alterations
speciﬁc for SSc.
In details, patients with frequent giant capillaries had signiﬁcantly
lower concentrations of Ang1 (15,943.12 ± 7880.90 pg/mL) than in
subjects with only few ones (26,730.94 ± 9749.93 pg/mL; p < 0.05).
The values of Ang1 in patients with frequent giants also tend to be
Table 2
Comparison of analysed angiogenic factors (Ang1, Ang2 and VEGF) serum le-
vels among SSc patients and healthy controls (U Mann-Whitney test).
Angiogenic factor Z p-Value Statistical signiﬁcance
VEGF 1409 0,159 p > 0,05
Ang1 −2622 0,009 p < 0,01
Ang2 4890 0,000 p < 0,001
Table 3
Ratios of serum levels of analysed angiogenic factors (Ang1, Ang2 and VEGF)
among SSc patients and healthy controls; data are given as mean ± standard
deviation (SD).
Ratio SSc patients Control group t p
Ang1/VEGF 95.17 ± 75.00 183.11 ± 137.73 −3.07 0.004
Ang2/VEGF 16,76 ± 26.48 10.29 ± 6,95 1.58 0.120
Ang1/Ang2 8.346 ± 4.523 17.612 ± 6.731 −6.374 0.00000014
Table 4
Correlations between analysed angiogenic factors (Ang1, Ang2 and VEGF) in
SSc patients group (Spearman rank correlation test);
Angiogenic factor Ang1 Ang2
Ang1 – –
Ang2 r=0,210
p > 0,05
–
VEGF r=0,251
p > 0,05
r=0,242
p > 0,05
M. Michalska-Jakubus, et al. Microvascular Research 125 (2019) 103881
3
lower with respect to SSc subjects without these abnormalities, but
between these two groups the diﬀerences did not reach statistical sig-
niﬁcance (p > 0.05). Concomitantly, patients with the presence of
giant capillaries (either few or frequent) exhibited signiﬁcantly in-
creased serum levels of VEGF (361.50 ± 254.09 pg/mL and
390.59 ± 245.50 pg/mL, respectively) than did those without
(168.19 ± 148.24 pg/mL; p < 0.05) (Fig. 2a). No diﬀerence was ob-
served for Ang2 serum levels.
Signiﬁcant elevation in serum VEGF was also associated with the
presence of multiple microhaemorrhages (405.36 ± 265.51 pg/mL)
when compared to NVC images without these abnormalities
(230.29 ± 158.58 pg/mL; p < 0.05). According to the presence or
absence of microhemorrhages, the diﬀerences in both Ang1 and Ang2
levels were not statistically signiﬁcant (p > 0.05); however, the lowest
values of Ang1 we observed in patients with frequent ones (Fig. 2b).
In addition, we detected signiﬁcant association between increased
levels of VEGF and the presence of pericapillary oedema
(410.84 ± 271.96 pg/mL vs. 263.69 ± 203.37 pg/mL) in patients
without this alteration; p < 0.05), whereas no diﬀerences were ob-
served for angiopoietins (Table 5).
Patients with severe disorganization of capillary distribution
showed signiﬁcantly higher levels of Ang2 (3051.96 ± 801.94 pg/mL)
than their counterparts with relatively well-preserved capillary ar-
rangement (2506.70 ± 1158.87 pg/mL; p < 0.05), as illustrated in
Fig. 3a.
It is worthy to emphasized that signiﬁcantly higher VEGF con-
centrations were found in SSc sera in case of avascular areas
(395.12 ± 256.27 pg/mL) when compared to patients with normal
capillary density (254.80 ± 213.61 pg/mL, p < 0.05) and this was
parallel to a tendency (although no signiﬁcant) towards lower Ang1
(Fig. 3b). No signiﬁcant diﬀerences were found for Ang2 levels
(p > 0.05).
Moreover, although serum levels of Ang2 and VEGF were both
slightly increased in patients with frequent ramiﬁed/bushy capillaries
than compared to group without or with only few neoangiogenetic
loops, the diﬀerences were not statistically signiﬁcant (Fig. 3a). No
signiﬁcant diﬀerences were found in the levels of Ang1 when focused
on the presence of ramiﬁed/bushy capillaries (p > 0.05).
The detailed associations of angiopoietins and VEGF serum levels
with NVC ﬁndings are summarized in Table 5.
4. Discussion
The major ﬁndings of this study to be discussed are as follows: i)
there is a signiﬁcant shift between serum Ang1 and Ang2 in favour of
Ang2 in SSc patients when compared to healthy controls; ii) the serum
Ang1/VEGF ratios in SSc patients are signiﬁcantly lower than in control
subjects; iii) presence of frequent giant capillaries on NVC is associated
with signiﬁcantly higher levels of VEGF and signiﬁcantly lower levels of
Ang1; iv) signiﬁcantly higher serum levels of VEGF are associated with
pericapillary oedema and multiple microhaemorrhages; v) higher
serum levels of VEGF and Ang2 predict more advanced capillary da-
mage as evident by avascular areas at the “Late” NVC pattern.
Recently, a steady shift from an early inﬂammatory and proangio-
genic environment to a late loss of angiogenesis and avascularity has
been suggested in SSc and manageable by optimised treatment algo-
rithms (Cutolo and Sulli, 2015; Matucci-cerinic et al., 2017).
As matter of fact, the advanced microvascular reactivity in SSc may
be due to the failure of some angiogenic steps, including dysregulated
balance of diﬀerent stimulating (proangiogenic) and inhibiting (an-
giostatic) factors (Avouac et al., 2008; Distler et al., 2003, 2004;
Mackiewicz et al., 2002; Manetti et al., 2016; Matucci-cerinic et al.,
2017; Solanilla et al., 2009; Sysa-Jędrzejowska et al., 2004).
In our previous study, we were the ﬁrst to show that angiopoietins
Ang1 and Ang2 are diﬀerentially expressed in the sera of patients with
SSc and that high Ang2 levels are associated with greater severity and
Fig. 1. Serum levels of Ang2 and VEGF according to the NVC pattern in NVC among SSc patients (n= 47). Data are given as medium (M), standard deviation (SD)
and range (Min.-Max.)
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higher activity of the disease as well as with more advanced capillary
damage and microvascular complications (i.e. active digital ulcers)
(Michalska-Jakubus et al., 2011). Our results were further conﬁrmed by
others, although some research reported divergent results (Dunne et al.,
2013; Riccieri et al., 2011; Avouac et al., 2013; Takahashi et al., 2013).
The present analysis was performed to evaluate the possible impact
of altered angiopoietins/VEGF balance on morphological derangement
of capillaries and angiogenic “switch” with ﬁnal loss of vascular repair
as evident by advanced speciﬁc alteration in microvessel morphology
objectiﬁed by NVC in SSc patients.
To our knowledge, this is the ﬁrst study where serum levels of VEGF
have been correlated with both Ang1 and Ang2 values as well as with
detailed NVC ﬁndings, and the importance of Ang1/Ang2 and Ang1/
VEGF ratios was taken into account. The signiﬁcant shift between Ang1
and Ang2 in favour of Ang2 in our SSc patients when compared to
healthy controls is consistent with our previous report (Michalska-
Jakubus et al., 2011). This is also in agreement with the study of
Riccieri et al. (2011) who revealed a signiﬁcant increase of Ang2 in the
group of 65 SSc patients with respect to normal controls; however,
Ang1 has not been analysed. Dunne et al. (2013) also demonstrated the
contribution of the Ang1/Ang2/Tie2 system to ongoing vasculopathy in
SSc with higher ratios of Ang2/Ang1 in both dcSSc and lcSSc than in
healthy controls. In contrast, Takahashi et al. (2013) failed to detect
statistically signiﬁcant elevation of serum Ang2 levels in SSc patients
which might be partially due to either the smaller number of samples or
relatively higher dose of prednisone (20mg/d) in their study. Active
role of aberrant balance between Ang1 and Ang2 expression with Ang2
predominance has been documented also in other pathological condi-
tions characterized by profound endothelial damage, and aberrant new
vessels formation such as cardiovascular diseases, proliferative diabetic
retinopathy (PDR) or systemic lupus (SLE) (Campochiaro and Peters,
2016; Chong et al., 2004; Eklund and Saharinen, 2013; Joussen et al.,
2002; Lee et al., 2004; Lim et al., 2004, 2005; Kümpers et al., 2009; Lip
et al., 2004; Loukovaara et al., 2013; Patel et al., 2005; Rangasamy
et al., 2009; Watanabe et al., 2005). Constitutive Ang1/Tie2 signalling,
with an Ang1/Ang2 ratio in favour of Ang1 is pivotal for vascular
quiescence (Fagiani and Christofori, 2013; Loukovaara et al., 2013).
Ang1 is predominantly expressed in perivascular cells such as pericytes,
vascular smooth muscle cells and ﬁbroblasts. Ang2 is expressed by ECs,
and its production is regulated at the transcriptional level by various
growth factors, including VEGF and tissue hypoxia (Fagiani and
Christofori, 2013). Ang1 is an “endothelial survival and vascular sta-
bilizing factor”, that inhibits ECs activation/apoptosis and helps to
maintain structural integrity of mature vessels thus protects against
leakage, leukocyte inﬁltration and tissue ﬁbrosis. In turn, Ang2 inter-
feres with Ang1 and acts as a vessel-destabilizing cytokine, playing an
essential role in vascular remodelling (Asahara et al., 1998; Fagiani and
Christofori, 2013; Holash et al., 1999a; Joussen et al., 2002;
Maisonpierre et al., 1997; Papapetropoulos et al., 1999; Suri et al.,
1996; Thurston et al., 2000; Thurston, 2002). Therefore, Ang1 in-
suﬃciency with shifting towards Ang2, might lead to loss of ECs ad-
hesion and integrity of the vessel wall permitting vessel dilatation and
leakage (Eklund and Saharinen, 2013; Fagiani and Christofori, 2013;
Gamble et al., 2000; Harfouche et al., 2002; Joussen et al., 2002; Kim
et al., 2000a; Koh, 2013; Loukovaara et al., 2013; Papapetropoulos
et al., 2000; Shapiro et al., 2017; Takahashi et al., 2013). In accordance,
in mice lacking Ang1 endothelial cells are aberrantly rounded and
poorly associated with periendothelial cells and matrix, thus vessels
have the dilated appearance resembling SSc giant capillaries (Suri et al.,
1996). In PDR up-regulation of Ang2 plays a major role in initial
Fig. 2. Serum levels of Ang1 and VEGF according to the absence/presence of giant capillaries (a) and microheamorrhages (b) in NVC among SSc patients (n=47).
Data are given as medium (M), standard deviation (SD) and range (Min.-Max.)
M. Michalska-Jakubus, et al. Microvascular Research 125 (2019) 103881
5
pericyte loss and ECs degeneration, and results in capillary remodelling
similar to those of SSc microangiopathy, including increased vascular
permeability, presence of microaneurysms, subsequent capillary loss
and pathological neovascularization with progressive ﬁbrosis
(Campochiaro and Peters, 2016; Loukovaara et al., 2013; Patel et al.,
2005; Saharinen et al., 2017; Shapiro et al., 2017; Watanabe et al.,
2005).
Moreover, Ang1 appears to antagonize VEGF action in dermal ca-
pillaries preventing vascular collapse (Detmar et al., 1998; Dvorak,
2002; Eklund and Saharinen, 2013; Fagiani and Christofori, 2013;
Gamble et al., 2000; Kim et al., 2001; Koh, 2013; Roberts and Palade,
1995; Thurston et al., 2000; Thurston, 2002). In our SSc group, al-
though VEGF serum levels did not diﬀer between patients and healthy
controls, Ang1/VEGF ratio was signiﬁcantly lower indicating shift be-
tween Ang1 and VEGF in favour of VEGF. This was especially evident in
those patients who presented pericapillary oedema, frequent giant
loops and microhaemorrhages on NVC. These NVC features represent
progressive steps in the development of SSc microangiopathy (Distler
et al., 2002, 2004; Frech et al., 2012; Matucci-Cerinic et al., 2013,
2017). Thus our results might raise the suggestion that relative deﬁ-
ciency of Ang1 with shifting towards Ang2 and VEGF as observed in our
study might underlay early SSc-speciﬁc vascular changes. In fact, ex-
perimental studies have shown that prolonged and uncontrolled over-
expression of VEGF in the skin of transgenic mice might have paradox
eﬀects leading to formation of irregular, chaotic capillary network of
increased permeability, tissue oedema and microhaemorrhages due to
changes in endothelium ultrastructure (fenestration and gaps formation
between ECs) as well as irregularly shaped dilated vessels with slow
blood ﬂow which were similar to giant capillaries in SSc patients (Choi
et al., 2003; Detmar et al., 1998; Roberts and Palade, 1995). Distler
et al. (2002) have shown upregulation of VEGF in SSc skin and postu-
lated that this unremitting upregulation contributes to the development
of irregularly shaped giant capillaries.
In our group of SSc patients higher levels of serum VEGF were also
signiﬁcantly associated with capillary loss. It increased concentrations
were strongly associated with avascular areas and tended to be elevated
in patients with “Late” NVC pattern. This is in accordance with several
studies that have reported markedly increased VEGF in SSc skin and
serum despite clear evidence of an insuﬃcient angiogenic response
(Avouac et al., 2013; Choi et al., 2003; Chora et al., 2015; Distler et al.,
2002, 2004; Mackiewicz et al., 2002; Manetti et al., 2010). This is also
in agreement with notion of inverse correlation between serum VEGF
levels and capillary density with signiﬁcantly higher VEGF concentra-
tions in SSc patients with the “Late” NVC pattern, compared to patients
with the “Early” or “Active” NVC patterns reported by other authors
(Avouac et al., 2013; Choi et al., 2003). In the study by Avouac et al.
(2013), higher serum VEGF levels remained independently associated
with the “late” NVC pattern and history of digital ulcers in multivariate
analysis suggesting a role for VEGF in endothelial injury and repair in
SSc. The same ﬁndings have been observed in SLE: signiﬁcantly higher
VEGF serum levels have been detected in patients with decreased ca-
pillary density (Moneib et al., 2012). On the contrary, Riccieri et al.
(2011) did not ﬁnd correlations between VEGF serum levels and ca-
pillaroscopic patterns in SSc.
The fact that VEGF is a potent angiogenic factors makes our ob-
servations somewhat intriguing. Possible clariﬁcation of this phe-
nomena is that increase of VEGF in the presence of capillary loss may be
a compensatory mechanism, however insuﬃcient to stimulate eﬀective
Table 5
Serum concentrations (pg/mL) of Ang1, Ang2 and VEGF in patients with SSc with respect to selected NVC ﬁnding; data are given as mean ± standard deviation
(SD).
NVC ﬁndings Status SSc patients N (%) Angiopoietin-1 (Ang1) Angiopoietin-2 (Ang2) VEGF
Mean ± SD Mean ± SD Mean ± SD
Pericapillary oedema Present 26 (55.32) 20,690.76 ± 9502.33 3034.79 ± 1083.34 410.84 ± 271.96
absent 21 (44.68) 22,873.63 ± 13,761.88 2501.19 ± 896.09 263.69 ± 203.37⁎
Capillary array r. w-p 13 (27.66) 19,182.65 ± 11,862.53 2506.70 ± 1158.87 297.14 ± 247.78
Mild disorg. 19 (40.43) 21,104.45 ± 11,888.06 2652.36 ± 1038.76 302.25 ± 275.86
Severe disorg. 15 (31.91) 24,529.80 ± 10,885.15 3051.96 ± 801.94⁎⁎ 391.87 ± 202.17
Loss of capillaries No evident 12 (25.53) 21,690.49 ± 11,299.88 2655.40 ± 1223.53 329.14 ± 238.23
Moderate 21 (44.68) 20,748.32 ± 11,116.23 2688.73 ± 1040.67 273.06 ± 229.38
Severe 14 (29.79) 23,021.83 ± 12,952.88 2888.09 ± 798.05 414.26 ± 266.14
Avascular areas Present 25 (53.19) 19,040.75 ± 10,367.62 2829.96 ± 899.98 395.12 ± 256.27
Absent 22 (46.81) 23,976.39 ± 12,176.12 2636.92 ± 1133.47 254.80 ± 213.61⁎⁎⁎
Enlarged capillaries Not present 8 (17.02) 23,003.35 ± 9007.48 2395.15 ± 1023.57 318.25 ± 197.29
Few 24 (51.06) 23,548.31 ± 13,150.61 2732.66 ± 775.30 357.14 ± 262.98
Frequent 15 (31.92) 17,941.32 ± 9439.76 2957.20 ± 1043.88 291.08 ± 247.89
Giant capillaries Not present 30 (63.83) 22,032.35 ± 12,365.39 2810.97 ± 926.40 168.19 ± 148.24
Few 8 (17.02) 26,730.94 ± 9749.93 2560.65 ± 1221.49 361.50 ± 254.09^
Frequent 9 (19.15) 15,943.12 ± 7880.90⁎⁎⁎⁎ 2660.79 ± 1175.66 390.59 ± 245.50^
Ramiﬁed/bushy capillaries Not present 26 (55.32) 20,764.79 ± 10,100.96 2544.06 ± 1040.87 323.02 ± 276.68
Few 16 (34.04) 21,677.55 ± 12,809.78 2866.75 ± 923.90 299.17 ± 207.50
Frequent 5 (10.64) 26,316.15 ± 15,485.24 3349.56 ± 981.36 459.64 ± 161.79
Micro-haemorrhages Not present 25 (53.19) 23,379.33 ± 11,901.87 2856.83 ± 974.94 230.29 ± 158.58
Few 15 (31.91) 20,925.20 ± 10,927.86 2516.79 ± 994.74 270.75 ± 259.86
Frequent 7 (14.89) 17,134.97 ± 11,573.02 2798.40 ± 1229.96 405.36 ± 265.51^^
NVC pattern Early 14 (29.79) 19,587.61 ± 11,493.55 2435.35 ± 1064.43 294.85 ± 237.76
Active 14 (29.79) 18,818.26 ± 8755.21 2323.53 ± 940.69 252.68 ± 234.59
Late 19 (40.42) 24,921.13 ± 12,776.79 2899.19 ± 788.37^^^ 411.48 ± 245.78
r. w-p= relatively well-preserved; mild disorg. = mild disorganization; severe disorg. = severe disorganization.
⁎ p < 0.05 for comparison between presence and absence of pericapillary oedema.
⁎⁎ p < 0.05 for comparison between severe disorganization of capillary array and relatively well-preserved capillary distribution.
⁎⁎⁎ p < 0.05 for comparison between presence and absence of avascular areas.
⁎⁎⁎⁎ p < 0.05 for comparison between presence of frequent or few giant capillaries.
^ p < 0.05 for NVC without giant capillaries when compared to NVC with either frequent or few giant capillaries.
^^ p < 0.05 for comparison between frequent microhaemorrhages and NVC without these ﬁnding.
^^^ p < 0.05 for comparison between late and active NVC pattern.
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angiogenic response with regrowth of functional vessels, or the increase
concerns primarily the antiangiogenic VEGF165b isoform (Avouac
et al., 2013; Choi et al., 2003; Chora et al., 2015; Distler et al., 2004;
Manetti et al., 2010, 2011, 2013, 2016). It might also be explained by
concomitant altered levels of other angiogenic or angiostatic factors
(Chora et al., 2015; Dunne et al., 2013; Michalska-Jakubus et al., 2011;
Riccieri et al., 2011). It ﬁts well our observation that in patients with
avascular areas increased VEGF was parallel to a tendency towards
lower Ang1. Recent studies indicate that Ang1 activate angiogenic
signalling (ECs migration, tubule formation and ECs survival) and
generate neovascularization in ischaemic tissue cooperatively with
VEGF and, as a result of insuﬃcient Ang1 availability, a decreased
number of matured vessels and scarce branching are observed that
corresponds with “Late” NVC pattern in SSc (Asahara et al., 1998;
Eklund and Saharinen, 2013; Fagiani and Christofori, 2013; Gamble
et al., 2000; Harfouche et al., 2002; Hayes et al., 1999; Holash et al.,
1999b; Kim et al., 2000a, 2000b; Koblizek et al., 1998; Koh, 2013;
Papapetropoulos et al., 1999; Suri et al., 1996, 1998; Thurston, 2002).
Thus, it could be supposed that, although increased VEGF might po-
tentially stimulate angiogenic response, concomitant Ang1 in-
suﬃciency as observed in our patients with capillary loss might lead to
regression/collapse of newly formed immature microvessels resulting in
deﬁcient angiogenesis and extensive areas of desertiﬁcation in SSc.
Consequently, in our patients with advanced capillary loss as evi-
dent by “Late” NVC pattern signiﬁcantly elevated Ang2 levels were
parallel to only slight increase in VEGF when compared to “Early” or
“Active” scleroderma patterns. Similarly to our results, Riccieri et al.
(2011) reported that plasma levels of Ang2 were markedly increased
whereas VEGF concentrations did not diﬀer in SSc patients with “Late”
NVC pattern. In contrast, Avouac et al. (2013) did not ﬁnd any diﬀer-
ences in Ang2 levels with respect to diﬀerent NVC patterns, although
they reported signiﬁcantly higher VEGF concentrations in patients with
late stage of microangiopathy.
Our notion corresponds with in vitro observations that sustained
elevation of Ang2 expression disrupts the formation of capillary-like
structures and impairs angiogenesis (Chen and Stinnett, 2008; Holash
et al., 1999a; Huang and Bao, 2004; Lee et al., 2006; Maisonpierre
et al., 1997; Reiss et al., 2007).
While almost absent in quiescent vasculature, Ang2 expression is
dramatically up-regulated upon angiogenic activation of the en-
dothelium and increases sensitivity to other proangiogenic factors such
as VEGF (Asahara et al., 1998; Eklund and Saharinen, 2013; Fagiani
and Christofori, 2013; Fiedler et al., 2004; Holash et al., 1999a, 1999b;
Kümpers et al., 2009; Lind et al., 2005; Loughna and Sato, 2001; Peters
et al., 2004; Tait and Jones, 2004; Wen et al., 2003; Yu and
Stamenkovic, 2001). The net outcome of Ang2 function is, however,
contextual. It facilitates angiogenesis with sprouting of new blood
vessels in the presence of VEGF but initiates vessel regression and im-
paired revascularization if the activity of VEGF is insuﬃcient (Fagiani
and Christofori, 2013; Hammes et al., 2004; Holash et al., 1999a; Lobov
et al., 2002; Loughna and Sato, 2001; Loukovaara et al., 2013; Oh et al.,
1999; Reiss et al., 2007; Shapiro et al., 2017; Takahashi et al., 2013). In
fact, hindlimb ischemia–induced collateral artery growth and angio-
genesis are signiﬁcantly impaired in mice with transgenic over-
expression of Ang2. Moreover, although Ang2 levels correlates with
newly formed endoglin positive vessels in tumor tissue, it is not related
to the density of vessels stained with von Willebrand factor (vWf) that
primarily marks mature vessels (Lind et al., 2005; Maisonpierre et al.,
Fig. 3. Serum levels of Ang2 according to the presence/absence of abnormal shapes (i.e. ramiﬁed/bushy capillaries) and disorganization of capillary array in NVC
(a); serum levels of Ang1 and VEGF according to the absence/presence of avascular areas in NVC (b) among SSc patients (n=47). Data are given as medium (M),
standard deviation (SD) and range (Min.-Max.)
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1997; Reiss et al., 2007; Tanaka et al., 2002). Thus, it could be supposed
that markedly increased Ang2 observed in our SSc patients might un-
derlay the loss of eﬃcient angiogenesis and severe disorganization of
capillary array despite the preserved expression of VEGF. Finally, in-
creased Ang2 levels might also be responsible for TGFβ-mediated in-
hibition of VEGF-induced endothelial tube formation (Fagiani and
Christofori, 2013).
Importantly, our results seem to reﬂect changes speciﬁcally in mi-
crocirculation since it has been reported that hypoxia–induced ex-
pression of Ang2 takes place exclusively in EC of microvessels while it is
undetectable in ECs of large vessels (Mandriota and Pepper, 1998).
We realize the possible limitations of the study is a relatively small
number of subjects, especially when calculating associations of agio-
poietins and VEGF in particular capillaroscopic groups as well as that
pan-VEGF instead of its pro- and antiangiogenic isoforms has been
analysed. Thus it needs further evaluations.
5. Conclusions
In the present study we suggested for the ﬁrst time that dysregula-
tion of angiopoietins/VEGF system with shift towards Ang2 and VEGF
and decrease in Ang1 levels may play a role in progression of SSc-
speciﬁc microangiopathy from capillary enlargement and collapse to
aberrant vessel repair and ﬁnal loss of angiogenesis (Fig. 4). According
to our results, VEGF levels seem to be increased early in SSc but in face
of attenuated Ang1 it might lead to ectatic microvessels of increased
permeability as reﬂected by giants and microhaemorrhages typical for
an “Active” NVC pattern. Elevated levels of VEGF appeared to be sus-
tained also in advanced stages of microangiopathy and correspond with
capillary loss (“Late” NVC pattern). With respect to our results, this
might be also partially explained by the relative advantage of Ang2 that
increase later in disease progress and result in advanced vascular da-
mage. Taken together, we identiﬁed that altered Ang1/Ang2 proﬁle
might underlay loss of angiogenesis in SSc despite increase in VEGF and
may be one of the essential factors promoting SSc-speciﬁc micro-
angiopathy. Moreover, since Ang1 is an “endothelial survival factor”, it
is possible that its relative insuﬃciency in SSc patients, as revealed in
our study, might be the mechanism underlying dysfunction and damage
of ECs thought to be a primary event in disease pathogenesis.
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